Supporting the “Good” Gut Microbes

During systemic infection, mice kick-start the production of a specific sugar to feed and protect the beneficial bacteria in their guts while fighting pathogenic strains.

Written byAnna Azvolinsky
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Mouse small intestine villi stained for fucose-attached proteins. JOSEPH PICKARD, UNIVERSITY OF CHICAGOMice with systemic bacterial infections induce a pathway that makes a sugar called fucose readily available to feed the beneficial microbiota in the small intestine, according to a study published today (October 1) in Nature. This newly uncovered protective mechanism helps maintain the “good” bacterial populations in the gut while the animal is sick—and appears to protect against further infections.

“The most interesting aspect of this study is that the host is responding to a systemic microbial infection signal by altering glycans on intestinal epithelial cells, and this in turn increases host fitness in a microbiota-dependent manner,” said Laurie Comstock, a microbiologist at the Brigham and Women’s Hospital in Boston who wrote an editorial accompanying the study but was not involved in the work.

In the event of systemic bacterial infection, the host will try to neutralize or kill the harmful bacteria—known as a resistance response—and mitigate the negative impacts of the infection without directly targeting the pathogens—through what’s called a tolerance response. The innate immune system is known to mediate resistance mechanisms to these infections partly by releasing the cytokine IL-22 from innate lymphoid ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies